MedTrace Logo

A Placebo-controlled Trial of Chronic Total Occlusion Percutaneous Coronary Intervention for the Relief of Stable Angina

NCT05142215 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-11-20

No results posted yet for this study

Summary

ORBITA-CTO Pilot is a double blinded randomised placebo-controlled trial comparing the effects of chronic total occlusion percutaneous coronary intervention versus placebo on symptoms of angina in patients with background optimal medical therapy.

Conditions

  • Stable Angina
  • Chronic Total Occlusion of Coronary Artery

Interventions

PROCEDURE

Percutaneous coronary intervention

Percutaneous coronary intervention using drug eluting stents and contemporary CTO PCI techniques on background of optimal medical therapy.

PROCEDURE

Placebo percutaneous coronary intervention

Placebo percutaneous coronary intervention procedure on background of optimal medical therapy.

Sponsors & Collaborators

  • Imperial College London

    collaborator OTHER

  • Mid and South Essex NHS Foundation Trust

    lead OTHER

Principal Investigators

  • John Davies, MRCP PhD · Essex Cardiothoracic Centre, UK

  • Sarosh Khan, MRCP · Essex Cardiothoracic Centre, UK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-19
Primary Completion
2025-10-21
Completion
2025-10-21

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05142215 on ClinicalTrials.gov